Biotime Aktie [WKN: 905313 / ISIN: US09066L1052]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Biotime IncShs

31.05.22		Brooklyn ImmunoTherapeutics CEO Quits, Names Interim Replacement; Andrew Jackson Is New CFO (RTTNews)
15.09.21		Factor Bioscience Celebrates 10th Anniversary with Grand Opening of ISO Class 7 Cleanroom Facility in Cambridge, Massachusetts (PR Newswire)
15.11.19		Lineage Cell Therapeutics Provides Update on SCiStar Clinical Study and OPC1 Spinal Cord Injury Program (Businesswire)
12.11.19		Lineage Cell Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Update (Businesswire)
05.11.19		Lineage Cell Therapeutics to Report Third Quarter 2019 Financial Results and Provide Business Update on November 12, 2019 (Businesswire)
28.10.19		Lineage Cell Therapeutics to Host Therapeutic Area Experts at Solebury Trout Investor Event on November 15, 2019 (Businesswire)
23.10.19		Lineage Cell Therapeutics Presents Encouraging Data on Vision Restoration Program at Society for Neuroscience’s 49th Annual Scientific Meeting (Businesswire)
22.10.19		Lineage Cell Therapeutics to Present at Dawson James Securities 5th Annual Small Cap Growth Conference on October 29, 2019 (Businesswire)
14.10.19		Lineage Cell Therapeutics Presents New OpRegen® Data at American Academy of Ophthalmology Annual Meeting (Businesswire)
07.10.19		Lineage Cell Therapeutics to Chair Session and Present Data on Vision Restoration Program at Society for Neuroscience’s 49th Annual Scientific Meeting on October 23, 2019 (Businesswire)
30.09.19		Lineage Cell Therapeutics to Present New OpRegen® Data at American Academy of Ophthalmology Annual Meeting on October 14, 2019 (Businesswire)
26.09.19		Lineage Cell Therapeutics to Present at 2019 Cantor Global Healthcare Conference on October 4, 2019 (Businesswire)
25.09.19		Lineage Cell Therapeutics Provides Update on Renevia® Commercialization Plans (Businesswire)
23.09.19		Lineage Cell Therapeutics to Present at 2019 Cell & Gene Meeting on the Mesa on October 3, 2019 (Businesswire)
19.09.19		Lineage Cell Therapeutics Receives CE Mark Approval for Renevia® (Businesswire)
06.08.19		Ausblick: Biotime vermeldet Zahlen zum jüngsten Quartal (finanzen.net)
31.07.19		BioTime Announces Name Change to Lineage Cell Therapeutics (Businesswire)
11.07.19		BioTime Initiates Dosing in Phase I/IIa Clinical Study of OpRegen for Treatment of Dry-AMD Utilizing Orbit Subretinal Delivery System (Businesswire)
02.07.19		BioTime Conducts Sale of Shares in OncoCyte Corporation (Businesswire)
22.05.19		BioTime Announces Appointment of General Counsel (Businesswire)
10.05.19		BioTime Awarded $2.5 Million Grant from the Israel Innovation Authority for Continued Development of OpRegen® (Businesswire)
09.05.19		BioTime Reports First Quarter 2019 Financial Results and Provides Business Update (Businesswire)
07.05.19		Ausblick: Biotime stellt das Zahlenwerk zum vergangenen Quartal vor (finanzen.net)
06.05.19		BioTime Announces Issuance of U.S. Patent for Method of Reducing Cavitation in Patients with Acute Spinal Cord Injury (Businesswire)
03.05.19		BioTime to Report First Quarter 2019 Financial Results and Provide Business Update on May 9, 2019 (Businesswire)
02.05.19		BioTime Presents Updated Data from OpRegen® Phase I/IIa Clinical Study at the Association for Research in Vision and Ophthalmology Annual Meeting (Businesswire)
26.04.19		BioTime to Present SCiStar Clinical Study Top-Line Data at the 26th Annual American Society for Neural Therapy and Repair Conference (Businesswire)
16.04.19		BioTime to Present Data from OpRegen® Phase I/IIa Clinical Study at the Association for Research in Vision and Ophthalmology Annual Meeting (ARVO 2019) (Businesswire)
18.03.19		BioTime to Present at Oppenheimer & Co. 29th Annual Healthcare Conference on March 20, 2019 (Businesswire)
14.03.19		BioTime Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update (Businesswire)
12.03.19		Ausblick: Biotime legt Zahlen zum jüngsten Quartal vor (finanzen.net)
11.03.19		BioTime Announces Closing of Acquisition of Asterias Biotherapeutics Creating Leading Cell Therapy Company (Businesswire)
07.03.19		BioTime to Report Fourth Quarter and Full Year 2018 Financial Results on March 14th, 2019 (Businesswire)
04.03.19		BioTime to Present at the 14Th Annual Scientific Meeting of the Association for Ocular Pharmacology and Therapeutics (AOPT 2019) on March 10, 2019 (Businesswire)
02.01.19		BioTime to Present at 2019 Biotech Showcase Investor Conference on January 7, 2019 (Businesswire)
04.12.18		BioTime Announces Publication of Positive Preclinical Results Utilizing Proprietary HyStem® Platform in Ischemic Stroke (Businesswire)
29.11.18		BioTime to Present at the LD Micro 11th Annual Main Event Investor Conference on December 5th, 2018 (Businesswire)
09.11.18		NantKwest Turning Heads, AUTL To Report Data In Dec., PTLA Marches Ahead (RTTNews)
08.11.18		BioTime and Asterias Biotherapeutics Enter Into Definitive Merger Agreement to Create Leading Cell Therapy Company (Businesswire)
08.11.18		BioTime Reports Third Quarter 2018 Financial Results and Provides Business Update (Businesswire)
06.11.18		BioTime Announces Update to Third Quarter 2018 Financial Results Conference Call (Businesswire)
06.11.18		Ausblick: Biotime stellt das Zahlenwerk zum vergangenen Quartal vor (finanzen.net)
05.11.18		BioTime Receives Second Installment Payment of $10.8 Million From Juvenescence Ltd. (Businesswire)
30.10.18		BioTime to Report Third Quarter 2018 Financial Results on November 8th, 2018 (Businesswire)
29.10.18		BioTime Presents New OpRegen® Data at American Academy of Ophthalmology Annual Meeting (Businesswire)
25.10.18		BioTime Announces November 16, 2018 Record Date and November 28, 2018 Distribution Date for the Distribution of Age-X Therapeutics Shares (Businesswire)
22.10.18		BioTime to Present New OpRegen® Data at American Academy of Ophthalmology Annual Meeting on October 28th (Businesswire)
27.09.18		BioTime to Present at the Upcoming Ladenburg Thalmann and MicroCap Conferences (Businesswire)
25.09.18		BioTime to Participate on Industry Perspectives Roundtable at NEI Audacious Goals in Regenerative Medicine Workshop: Pathways for Retinal Cell Replacement Therapies (Businesswire)
21.09.18		BioTime Warrants to Expire on October 1, 2018 (Businesswire)

1 | Weiter

Newssuche

Meistgelesene Nachrichten

Drohende Korrektur? Experte schlägt Alarm bei der NVIDIA-Aktie

Neuer Rekord nicht mehr weit: Bitcoin, Ethereum, Litecoin & Co.: Wie sich die Kryptokurse am Mittag entwickeln

Pierer Mobility-Aktie zweistellig im Plus: Pierer dementiert Mateschitz-Einstieg bei KTM

UN-Klimagipfel in Baku: Baerbock warnt vor 'Killerstürmen'

Angespannte Stimmung in Frankfurt: LUS-DAX gibt am Nachmittag nach

Nah an 100.000er Marke: Bitcoin, Dogecoin, Ethereum & Co. am Vormittag

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2024 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	27.11.2024 01:36
Kaufwert:	EUR
	Hinzufügen Speichern